Business Context and Reporting Period
This Form 8-K Current Report was filed by Pliant Therapeutics, Inc. on March 27, 2026, regarding events occurring on March 30, 2026. The Company is a Delaware corporation with its principal executive offices in South San Francisco, CA, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "PLRX."
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on a corporate action regarding equity financing arrangements.
Material Changes
- New Sales Agreement: The Company entered into a new "at-the-market" (ATM) Sales Agreement with Leerink Partners LLC, effective March 30, 2026.
- Offering Capacity: Under the new agreement, the Company may offer and sell shares of common stock with an aggregate offering price of up to $50.0 million.
- Termination of Prior Agreement: The Company terminated its previous Controlled Equity Offering Sales Agreement dated July 2, 2021, with Cantor Fitzgerald & Co., effective March 27, 2026.
- Historical Usage: No shares were sold under the terminated 2021 Sales Agreement prior to its termination.
- Penalties: The Company is not subject to any termination penalties related to the 2021 Sales Agreement.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, management commentary on future performance, or a discussion of risks beyond the standard disclosure that the description of the terminated 2021 Sales Agreement is qualified by reference to the original filing. The primary strategic implication is the shift in sales agent for future equity offerings.
Investor Verification Checklist
- Verify the terms of the new Sales Agreement with Leerink Partners LLC, including commission rates and any lock-up provisions.
- Confirm the Company's current cash position and burn rate to assess the necessity of the $50.0 million ATM facility.
- Review the Company's recent stock price volatility to evaluate the potential dilution impact of future sales under the new program.
- Check for any subsequent filings indicating the first sale of shares under the new 2026 Sales Agreement.